Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections for Glycemic Management in Pregnant Women With Type 1 Diabetes: A Systematic Review and Meta-Analysis

CSII offers measurable metabolic advantages during pregnancy by lowering glycosylated hemoglobin levels and reducing insulin needs. Nevertheless, these benefits do not consistently translate into improved maternal or neonatal outcomes and may be offset by higher obstetric and neonatal complication rates. Further well-powered randomized controlled trials are required to clarify the role of CSII and to balance metabolic gains against obstetric risks in managing pregnant women with T1DM.

Authors

Institutions

Publication Details

Journal
AACE Endocrinology and Diabetes
Published
2025-08-22
DOI
https://doi.org/10.1016/j.aed.2025.08.005
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections for Glycemic Management in Pregnant Women With Type 1 Diabetes: A Systematic Review and Meta-Analysis

Lilian Aly, Jobby John, Antonio Ramı́rez, Ricardo Correa Marquez et al.
AACE Endocrinology and Diabetes
Diabetes Management and Research
article

Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections for Glycemic Management in Pregnant Women With Type 1 Diabetes: A Systematic Review and Meta-Analysis

Lilian Aly, Jobby John, Antonio Ramı́rez, Ricardo Correa Marquez, Ernesto Calderón Martinez, Marı́a Luisa Nieto, Victor Sebastian Arruarana, Stephani Carolina Salvatierra Moreno, Jonathan Víctor Salazar Ore, Stephin Zachariah Saji, Gabriela D Briceño Silva, Olivia Murga, Hugo Lana Devita
article en

Abstract

CSII offers measurable metabolic advantages during pregnancy by lowering glycosylated hemoglobin levels and reducing insulin needs. Nevertheless, these benefits do not consistently translate into improved maternal or neonatal outcomes and may be offset by higher obstetric and neonatal complication rates. Further well-powered randomized controlled trials are required to clarify the role of CSII and to balance metabolic gains against obstetric risks in managing pregnant women with T1DM.

AACE Endocrinology and DiabetesVol. 12(4)
Universidad de Ciencias Medicas (CR), Cleveland Clinic (US), Ilia State University (GE), Universidad de Oriente (VE), Universidad de Los Andes (VE), Pontificia Universidad Javeriana (CO), Universidad de Buenos Aires (AR), Dr. Somervell Memorial CSI Medical College and Hospital (IN), Brookdale University Hospital and Medical Center (US), Our Lady of Fatima University (PH), The University of Texas Health Science Center (US), Fundación Ciencias Exactas y Naturales (AR), Universidad Central de Venezuela (VE), The University of Texas Health Science Center at Houston (US)
Zero hunger
Openalex Percentile: Top 70%
Diabetes Management and Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.